Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - GlobeNewswire
Unicycive Therapeutics 宣布美國 FDA 接受針對 Oxylanthanum Carbonate (OLC) 的新藥申請 (NDA),用於治療接受透析的慢性腎病患者的高磷血症。
🕗 11-11 20:01 🔎站內相關文獻 🔗新聞連結